Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jan 10 2019

Full Issue

Tech Companies Are Done Waiting For Drugmakers To Provide Miracle Cure On Alzheimer's

There's been a decades-long stagnation when it comes to drug-based treatments for Alzheimer's so a cadre of tech companies are rushing in to fill the gap with digital products, robotics and software. In other public health news: fertility rates, artificial sweeteners, vaccines, hormone replacements and sick days.

Stat: With Search For Alzheimer's Drugs Failing, Tech Firms Offer Solutions 

The drug industry’s foundering search for an Alzheimer’s cure is fueling a parallel quest by technology companies to help patients and family caregivers cope with the disease by using virtual reality software, robotics, and novel communication tools. Several companies engaged in the effort gathered here on Wednesday to deliver a unified message: Waiting for pharma to deliver a miracle is a recipe for financial Armageddon, as the cost of treating Alzheimer’s is expected to quadruple, to more than $1 trillion in the U.S. by 2030, if no breakthrough treatments reach the market. (Ross, 1/10)

The Wall Street Journal: How Fertility Rates Vary Around The Country

The birthrate in America has been declining, but some places are more fertile than others, according to a new look at federal data that reveals significant variation in fertility rates around the country. Only South Dakota’s and Utah’s fertility rates reached the level needed to sustain the current population. The number of babies born in 2017, around 3.85 million, was the lowest since 1987. In order for the country’s population to essentially replace itself, researchers say that 2,100 babies should be born for every 1,000 women. In 2017, the total fertility rate—an estimate of the total number of children a woman will eventually have in her lifetime—was 1,765 births per 1,000 women, well below what is known as the replacement level. (Abbott, 1/10)

The New York Times: Artificial Sweeteners, Not Good, Not Bad

Artificial sweeteners offer no health benefits, a large review of studies found. But it found no proof that they do any harm, either. Researchers looked at 35 observational studies and 21 controlled trials of nonsugar sweeteners in children and adults. Some compared intake of sweeteners with no intake; others compared lower with higher intakes. They found no convincing evidence that nonsugar sweeteners had any effect in adults on eating behavior, cancer, cardiovascular disease, kidney disease, mood, behavior or cognition. (Bakalar, 1/9)

Miami Herald: Shingles Vaccine Shortage: Where To Get The Shot

Finding a place to get your first shot of the shingles vaccine, or second required dose, is getting as difficult as scoring “Hamilton” tickets. In South Florida alone, many pharmacy outlets at chains like Publix and Walgreens have reported problems obtaining vaccines and waiting lists are growing. (Cohen, 1/9)

The New York Times: Hormone Replacement Skin Patches Don’t Raise Risk For Blood Clots

Oral hormone replacement therapy, or H.R.T., increases the risk for potentially fatal blood clots. But a study in BMJ found that hormone replacement delivered through the skin by injection or skin patch entails no increased risk for blood clots. British researchers looked at 80,396 women who had blood clots while on various H.R.T. regimens, comparing them with 391,494 controls. (Bakalar, 1/9)

The New York Times: The Death Of The Sick Day

Adam Toren remembers the last time he crawled into bed, pulled the covers over his head and took off sick from work. “My whole family got wracked by the flu around 2006,” said Mr. Toren, a tech entrepreneur and writer. “Hopefully, that was the last time.” Thirteen years later, Mr. Toren, who lives in Phoenix, said he has not missed another day of work from illness, a streak of which he is exceedingly proud. To keep it going, “I monitor my sleep cycles,” he said, laying out the things he believes keep him healthy. “I don’t drink coffee. I drink specialty teas — Gyukuro, a Japanese tea. I take turmeric and resveratrol,” a supplement. (Kurutz, 1/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF